Trial Profile

A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ralinepag (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions
Acronyms ADVANCE EXTENSION
Sponsors Arena Pharmaceuticals; Pfizer; United Therapeutics Corporation

Most Recent Events

21 Apr 2025 According to United Therapeutics media release, Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025.
03 Apr 2025 Planned End Date changed from 1 Sep 2024 to 1 Dec 2026.
03 Apr 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com